2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…2019 American Transplant Congress
Alemtuzumab versus Anti-Thymocyte Globulin Induction in the Setting of Immediate Post-Renal Transplant Acute Tubular Necrosis in an Urban, Minority Patient Population
University of Illinois at Chicago, Chicago, IL
*Purpose: Post-renal transplant (RTx) delayed graft function (DGF) or slow graft function (SGF) increase the risk of rejection and impair allograft function. Lymphocyte depleting induction…2019 American Transplant Congress
Incidence of Viral Infections in Kidney Transplant Recipients with Alemtuzumab or Rabbit Antithymocyte Globulin Induction
1Tampa General Hospital, Tampa, FL, 2Florida Kidney Physicians, Tampa, FL
*Purpose: Monoclonal antibody therapy causes profound and sustained lymphocyte depletion thus increasing the risk of viral infections. While studies exist evaluating the outcomes of alemtuzumab…2019 American Transplant Congress
Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the effect of induction therapy on efficacy and safety outcomes of de novo renal transplant recipients (RTxR) receiving everolimus with reduced calcineurin…2019 American Transplant Congress
Living Donor Renal Transplantation without Any Induction Immunosuppression in Spousal Donors – Single Center Experience
Nephrology & Transplantation, Malabar Instiute of Medical Sciences, Calicut, India
*Purpose: Renal transplantation in India is primarily driven by living related donation; parents and spouse constitute 70% of donors in India. Some centres use induction…2019 American Transplant Congress
A Prospective, Randomized, Multicenter Trial of Bela-Based CNI Free and Steroid Withdrawal Immunosuppression: Best Trial Two Year Characterization of Rejection and Renal Function
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) was designed to compare two BELA-based early steroid withdrawal (ESW) regimens with a TAC-based ESW regimen…2019 American Transplant Congress
Effect of ATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients
Beijing Chao-yang Hospital, Beijing, China
*Purpose: Myeloid-derived suppressor cells (MDSCs) consist of heterogeneous myeloid progenitors and precursors that was first defined in cancer patients and are characterized by a immunoregulatory…2019 American Transplant Congress
Induction with Thymoglobulin in DCD Kidneys. Dose Effect and Predictors of Outcome
Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom
*Purpose: Thymoglobulin (ATG) is used only in few UK centres as induction. We have previously shown good results with ATG for pancreas transplants. The aim…2019 American Transplant Congress
Low Dose Thymoglobulin Has No Disadvantages to Standard Higher Dose: A Report of the Midwest Pediatric Nephrology Consortium
*Purpose: What is not known is whether a lower Thymoglobulin (ATG) induction dose provides safe and effective immunosuppression compared to a “standard” higher dose in…2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…
American Transplant Congress abstracts